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Outcome Measures in Polymyalgia Rheumatica. 
A Systematic Review
Cátia Duarte, Ricardo Jorge de Oliveira Ferreira, Sarah Louise Mackie, John Richard Kirwan,
and José António Pereira da Silva, on behalf of the OMERACT Polymyalgia Rheumatica
Special Interest Group
ABSTRACT. Objective. To identify the instruments used to assess polymyalgia rheumatica (PMR) in published
studies. 
Methods. A systematic literature review of clinical trials and longitudinal observational studies related
to PMR, published from 1970 to 2014, was carried out. All outcome and assessment instruments were
extracted and categorized according to core areas and domains, as defined by the OMERACT
(Outcome Measures in Rheumatology) Filter 2.0.
Results. Thirty-five articles (3221 patients) were included: 12 randomized controlled trials (RCT); 3
nonrandomized trials; and 20 observational studies. More than 20 domains were identified, measured
by 29 different instruments. The most frequently used measures were pain, morning stiffness, patient
global assessment and physician global assessment, erythrocyte sedimentation rate, and C-reactive
protein. The definition of outcomes varied considerably between studies.
Conclusion. The outcome measures and instruments used in PMR are numerous and diversely defined.
The establishment of a core set of validated and standardized outcome measurements is needed. 
(First Release November 15 2015; J Rheumatol 2015;42:2503–11; doi:10.3899/jrheum.150515)
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Polymyalgia rheumatica (PMR) is an inflammatory disease
with a lifetime risk estimated at 2.4% for women and 1.7%
for men1 and a peak incidence after 60 years of age. The
diagnosis of PMR relies on clinical and laboratory manifes-
tations, supported by a rapid, favorable response to glucocor-
ticoid (GC) therapy at medium doses (15–20 mg/day of
prednisone or equivalent). When untreated, PMR can cause
profound disability. GC remains the gold standard therapy
for PMR and is usually efficacious. However, the potential
toxicity of longterm GC therapy2 imposes the need to search
for safer alternatives. 
Future research in PMR requires the use of valid and
reliable outcome measures that encompass the relevant scope
of disease manifestations. A variety of outcomes have been
used to assess disease activity, including clinical features
(pain and morning stiffness), ultrasonography (US) variables,
and laboratory measures such as erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP) and interleukin-6 (IL-6)
levels. Composite scores of disease activity3, and definitions
of good response, remission and relapse have been
proposed3,4,5,6. However, these measures have not yet been
extensively validated in PMR and do not incorporate patient
viewpoints.
The Outcome Measures in Rheumatology (OMERACT)
initiative aims to develop core sets of outcome measures
capable of providing consistent estimates of the benefits of
interventions for each given condition in clinical trials7.
According to the OMERACT Filter 2.0, such core sets should
include at least 1 domain from each core area. Four core areas,
broad aspects of a health condition, are defined: 3 encompass
the “impact of health conditions” — life impact, resource use,
and death; and a fourth core area encompasses pathophysio-
logical manifestations8,9. This filter also considers domains,
as subspecifications within 1 area9,10. In order to be included
in a core set, a domain should be measurable by truthful,
discriminative, and feasible instruments9,11. 
The OMERACT PMR working group was formed to
define a core set of outcome measures to be used in future
clinical research in PMR. With the present systematic liter-
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ature review we aimed to supply this endeavor with objective
information on outcome measures currently used to assess
PMR disease activity and response to treatment. 
MATERIALS AND METHODS
Search strategy. The literature search was performed in MEDLINE,
CINAHL, Science Citation Index from the Web of Science, Cochrane
Library (Cochrane Central Register of Controlled Trials and Cochrane
Database of Systematic Reviews). The research strategy was based on the
following key words: [“Polymyalgia Rheumatica” (Medical Subject
Headings)], and covered material published from January 1, 1970 to June
30, 2014. 
Inclusion criteria. Studies were included if they: (1) used published classi-
fication criteria to select patients; (2) were written in English, French,
Portuguese, or Spanish languages; (3) followed a design of either clinical
trial or longitudinal observational study, and (4) were available in full text.
Studies that included heterogeneous patient samples and published data
that did not allow differentiating subjects with PMR from those with other
diseases (e.g., giant cell arteritis or late onset rheumatoid arthritis) were
excluded. 
Study selection. Titles, abstracts, and full reports of articles identified were
systematically and independently screened by 2 authors (CD and RF) with
regards to inclusion and exclusion criteria. In the first step, selection was
based on titles and abstracts. Full reports of articles selected in this phase
were evaluated (second step) to select articles to include in this systematic
review. Disagreements regarding selection of an article were discussed
between both reviewers until consensus was reached. Persistent disagree-
ments were resolved by a third evaluator (JAPS). 
Data extraction. During data extraction, special attention was given to
Patients and Methods and Results sections of each article. All data were
extracted using a standardized template designed for this review, which had
been piloted and improved, and which included study design, sample size,
followup period, outcome measures used, and the method of assessment. 
Each outcome was characterized according to the OMERACT Filter 2.0
considering core areas (pathophysiological manifestations, life impact, death,
resource use) and domains8.
RESULTS 
Results of the literature search and selection of articles are
presented in Figure 1. The electronic search strategy yielded
868 articles, 43 of which were selected, on the basis of title
and abstract, for further assessment/detailed review.
Ultimately, 35 studies12-21,22-31,32-41,42,43,44,45,46 met inclusion
criteria for this systematic review (Figure 1). Agreement
between the 2 reviewers was 96.6% and 100% for the first
and second steps of article selection, respectively. 
Included studies. Table 1 shows the study design character-
istics of included articles. Twelve of the included studies are
randomized drug trials, controlled against either placebo or
conventional PMR treatment12-21,22,23. Three are nonran-
domized interventional studies or ones without clear 
information about randomization24,25,26. Longitudinal obser-
vational studies represent more than one-half of selected
articles (20 of 35)27–36,37-46. One of these observational
studies36 is a longterm followup of an already included
RCT20. The study size ranged from 424 to 781 subjects32,41,
with followup periods varying between 14 days22 and 34
years32. All studies included a majority of females and
patients older than 50 years, which is in agreement with
classical PMR features47,48,49,50.
Studies identified in this literature review include
outcomes and instruments pertinent to all core areas defined
by OMERACT, except resource use. The core area most
represented is pathophysiological manifestations, which
included a total of 6 domains, followed by life impact with 5
domains (Table 2). 
Pain. Pain was used as an outcome in 17 studies12,13,14,15,
16,18,19,22,25,34,36,39,40,43,44,45,46
. A visual analog scale (VAS)
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Figure 1. Flow chart of the search and selection
process.
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Table 1. Characterization of the studies included in the analysis. 
Year First Author Study Design/ Intervention Sample PMR Definition / Followup
and Reference Protocol Size Stage of Disease
Randomized clinical trials
1987 Lund12 RCT, double blind, crossover Deflazacort vs 41 Bird / maintenance phase 12 wks
(after a single blind parallel prednisone, weight
3 arms) ratios of 1:1.2, 1:1.5, 
and 1:1.8
1995 Littman13 RCT, multicenter, Tenidap 120 mg/day + 32 Study definition/  15 wks
placebo controlled PDN 10 mg/day vs placebo + stable disease
PDN 10 mg/Day
1995 Krogsgaard14 RCT, double blind, controlled Deflazacort vs prednisolone 30 Bird / new diagnoses 12 mos
1995 Di Munno15 RCT, double blind, crossover Deflazacort vs 29 Study definition / 12 wks
methylprednisone new diagnoses
1996 Krogsgaard16 RCT, double blind, controlled Deflazacort vs prednisolone 30 Bird / new diagnoses 12 mos
1996 Ferraccioli17 RCT, open Prednisone 15 mg vs prednisone 24 Study definition / 12 mos
25 mg + MTX 10 mg/wk new diagnoses
1998 Dasgupta18 RCT, double blind, Methylprednisone depot 60 Study definition / 96 wks
multicenter vs prednisolone po new diagnoses
2000 Salvarani19 RCT, double blind placebo Shoulder injection of 40 mg 20 Healey / new diagnoses 7 mos
controlled of methylprednisone
2004 Caporalli20 RCT, multicenter, double blind, MTX 10 mg/wk + GC vs 72 Chuang / new diagnoses 18 mos
placebo controlled placebo + GC
2007 Salvarani21 RCT, multicenter, double blind, Infliximab 3 mg/kg 51 Healey / new diagnoses 52 wks
placebo controlled vs placebo
2010 Kreiner22 RCT, double blind, Etanercept 25 mg 2/wk 20 Chuang / New diagnoses 2 wks
placebo controlled vs placebo
2011 Björman23 RCT, crossover, double blind Casein vs protein-enriched 60 Rheumatologist definition* 20 wks
dairy product
Non-randomized clinical trials
2003 Salvarani24 Open, pilot, uncontrolled study Infliximab + prednisone 4 Healey / longstanding disease 49 wks
2007 Catanoso25 Clinical trial, open, uncontrolled Etanercept 25 mg 6 Healey / relapsing/ 36 wks
twice/wk, 24 wk longstanding
2011 Cimmino26 Clinical trial not randomized, Prednisone 12.5 mg/id 60 Bird / new diagnoses 6 mos
uncontrolled
Observational studies
1999 Weyand27 Prospective observational study NA 30 Study definition / new diagnoses 12-33 mos
2000 Cantini28 Prospective observational study NA 177 Healey / new diagnoses 5 yrs
2003 Myklebust29 Prospective observational  NA 65 Bird or Harlim / 1987-1997
study; gender-age matched controls any stage
2005 Salvarani30 Prospective observational study NA 94 Healey / new diagnoses 24 mos
2006 Boiardi31 Prospective observational study NA 112 Healey / new diagnoses 24 mos
2007 Kremers32 Prospective observational study NA 364 Chuand and Hunder / 1970-2004
new diagnoses
2007 Leeb33 Prospective observational study NA 39 Bird 18 mos
2007 Hutchings34 Prospective observational, multicenter study NA 129 Hazelman / new diagnoses 12 mos
2008 Binard35 Prospective observational study NA 89 Rheumatologist definition* Not defined
2008 Cimmino36 Longterm followup of RCT20 MTX 10 mg/wk 57 Chuang / new diagnoses 5 yrs
2008 Pulsatelli37 Prospective observational study NA 93 Healey / new diagnoses 24 mos
2009 Macchioni38 Prospective observational study NA 57 Healy / new diagnoses 41 mos
2010 Calvo39 Case Cohort study NA 20 ACR criteria (Chuang and  12 mos
Healey) / new diagnoses
2010 Jiménez-Palop40 Prospective observational, NA 59 Study definition / 12 wks
multicenter study new diagnoses
2011 Kang41 Prospective observational study NA 781 Rheumatologist definition* / 3 yrs
new onset cases
2012 Mazzantini42 Retrospective observational study NA 222 Bird / longstanding disease Not defined
2012 Cleuziou43 Prospective observational study NA 89 Rheumatologist definition* Not defined
2012 Matteson44 Prospective observational study NA 85 ACR/EULAR / new diagnoses 6 mos
2013 McCarthy45 Prospective observational study NA 60 Jones & Hazleman / new diagnoses 6 wks
2014 McCarthy46 Prospective observational study NA 60 Jones & Hazleman / new diagnoses 6 wks
*Autonomous clinical diagnoses by attending rheumatologist. PMR: polymyalgia rheumatica; RCT: randomized clinical trials; ACR: American College of
Rheumatology; EULAR: European League Against Rheumatism; PDN: prednisolone; MTX: methotrexate; GC: glucocorticoid; NA: not applicable.
 Journal of Rheumatology
The on December 15, 2015 - Published by www.jrheum.orgDownloaded from 
was commonly used to quantify pain, usually as a 0–10 cm
scale (11 studies). In 3 of them12,14,16, pain was graded using
an ordinal scale form “0” to “3.”
Most published reports do not provide a clear definition
of the pain being assessed. The description of pain local-
ization varies: “shoulder and pelvic girdle pain,”15 “proximal
pain,”34 “proximal muscle pain,”14,16 or “joint or muscle
pain.”13 Matteson and colleagues evaluated pain considering
different locations including shoulder, limbs, and global44.
None of the published reports specified the period of time
under evaluation when asking patients about their “pain.”
Morning stiffness. Stiffness, more commonly morning
stiffness, was considered in almost all the included
studies13,14,15,16,18,19,20,21,22,24,25,26,27,28,30,33,34,35,36,37,38,40,43,44,45,46.
It was evaluated as an independent outcome in 11
studies13,14,15,16,18,19,25,27,34,40,44, and was included as a
variable in composite disease activity scores or in the
definition of relapse/recurrence/remission in an additional 15
studies19,20,22,24,26,28,33,35,36,37,38,43,44,45,46.
Morning stiffness was measured in terms of duration
(“minutes”) in the majority of the studies. In 1 RCT18,
morning stiffness duration was reported in 1 study through a
4-point scale (1: < 30 min; 2: 30–60 min; 3 = 60–120 min;
and 4: > 120 min). In 2 studies, stiffness was graded from 0
to 3, where “0” means no symptoms; but it is unclear whether
severity, duration, or both was being assessed14,16. No infor-
mation is given to the meaning of the other values in the
scale. Only Weyand and colleagues27 evaluated the severity
of morning stiffness using a 0–10 cm VAS. Only 1 RCT13
and 1 observational study27 gave precise information about
the time interval under evaluation (“average of last week”).
Patient and physician global assessment. Patient Global
Assessment (PGA) of disease activity was measured in 9
studies13,19,22,25,27,33,35,38,46, always as a 0–10 cm VAS except
in 2 studies13,17, where a 5-point ordinal scale was used. 
Physician Global Assessment (PhGA) was used in 14
studies12,13,19,22,25,27,33,35,36,38,43,44,45,46, 12 of them as a 0–10
cm VAS and 213,27 as 5-point ordinal scales. 
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Table 2.Health areas, domains and instruments reported in the 35 selected articles. 
Core Area Domain No. of Studies Instrument No. of Studies Using 
the Instrument
Pathophysiological Laboratory markers 30 ESR 29
CRP 23
IL-6, fibrinogen 12
Ultrasonography 4 Girdles US evaluation 4
Pain 17 VAS 0–10 cm 11
VAS 0–100 mm 2
VAS 0–32 1
Grade 0–3 3
Morning stiffness 26 Duration (min) 11
Grade 4
Severity (VAS 0–10) 1
As a parameter of compositum measure or definition 15
Life impact PGA 9 VAS 0–10 7
5 point–scale 2
PhGA 14 VAS 0–10 12
5 point scale 2
PATSAT 1 Range 1–5 1
Function 5 HAQ 5
Quality of life 2 MOS–SF36 1
VAS 0-100 1
Death Mortality 1 SMR 1
Resource — 0 — —
Composite measures Disease activity 8 PMR-AS 8
Remission 6 Own definition 6
Recurrence/Relapse 8 Own definition 8
Contextual factors; Side effects 14 General 12
adverse events Bone mineral content 2
Vertebral fracture 2
Glucocorticoid therapy 6 Minimal dose 2
Cumulative dose 3
Discontinuation 4
Vascular disease 3 AMI, HF, CVA, PVD 3
AMI: acute myocardial infarction; PGA: patient global assessment; PhGA: physician global assessment; PATSAT: patient’s satisfaction with disease status;
CVA: cerebrovascular accident; HAQ: Health Assessment Questionnaire; HF: heart failure; PMR-AS: Polymyalgia Rheumatica Activity Score; PVD: peripheral
vascular disease; SMR: standardized mortality rate; SF-36: Medical Outcome Study Short Form 36; VAS: visual analog scale; IL-6: interleukin 6. 
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In 9 studies22,25,35,36,38,43,44,45,46 both PGA and PhGA
were included as a variable within a predefined composite
disease activity score. 
Two instruments were employed by a single study33: (1)
PGA of General Health and (2) Patient Satisfaction with
Disease Status (classification of disease state according to the
Austrian school mark system: 1 = excellent, 2 = good, 3
= average, 4 = moderate, 5 = unsatisfactory). 
Function and quality of life. Function was assessed in 5
observational studies34,36,38,44,46, 1 open label trial25, and 3
RCT21,22,23. In all studies, function was assessed through the
generic Health Assessment Questionnaire (HAQ)51. 
Health-related QoL was considered in 2 large observa-
tional studies34,44 and was assessed through the generic tool
Medical Outcome Study Short Form 36 Survey52. In a single
observational study46, QoL during the past month was
assessed using a 0–100 mm VAS, where 0 means normal and
100 the worst QoL. 
Other clinical outcomes. Elevation of upper limbs was
considered an outcome in some studies22,25,33,35,46, always
as a component of a composite disease activity score. Upper
limb elevation was measured on a 0–3 scale with the
following levels: 3 = no upper limb elevation; 2 = elevation
below shoulder level (< 90º); 1 = elevation at shoulder level
(90º); and 0 = elevation above shoulder level (> 90º). Muscle
function23 (hand grip strength and jump test), chair stand
test23, 10-meter walking23, and time to onset of fatigue
(hours)13 were used as outcomes in a single study each.
Intensity of fatigue reported by the patient, using 0–100 mm
VAS, was assessed in a single study44.
ESR and CRP. ESR12,13,14,15,16,17,18,19,21,22,24,25,26,27,28,30,
31,33,34,35,36,37,38,39,40,43,44,45,46 and CRP12,13,15,17,19, 21,23,24,
25,26,28, 30,31,33,34,35,36,37,38,40,43,44,45,46 were used in the
assessment of disease activity by most but not all RCT and
observational studies. 
Other laboratory measures. Other laboratory outcome
measures used in some observational and clinical trials
include serum fibrinogen12,15,16,45,46 and IL-6 levels19,22,
24,27,30,31,37
, mainly as experimental evaluations. 
Ultrasonography. US was used in 3 prospective observa-
tional studies38,40,44 and in 1 open label trial25. Different
studies used different evaluation protocols, there being no
formal proposal for the standardization of US evaluation of
response to therapy in PMR. Jiménez-Palop and colleagues
considered the evaluation of intraarticular synovitis at the
shoulder and hip, tenosynovitis, and bursitis in the shoulder.
This study demonstrated good inter and intraobserver relia-
bility (0.96 and 0.99, respectively) but no statistically signifi-
cant correlation was found with clinical and laboratory
variables of disease activity40.
Composite measures. Most of the studies integrated the
individual outcome measures into composite indices,
considered as response/relapse criteria or activity scores. This
is summarized in Table 3. Most of them defined relapse or
recurrence as the observation of new symptoms, increase of
ESR (usually > 30 mm), or increase of CRP (> 0.5 mg/dl or
1 mg/dl), after remission has been achieved, in patients
receiving GC or after discontinuation of GC, respectively.
Proposed response criteria include improvement of
symptoms and reduction/normalization of inflammatory
variables (ESR and CRP). In 2003, the European Colla-
borating Polymyalgia Rheumatica Group proposed a core set
of response criteria. These EULAR response criteria
comprise an improvement in VAS pain (obligatory) and at
least 3 of the following 4 items: CRP (mg/l) or ESR (mm/h),
morning stiffness (min), elevation of upper limbs (0–3), and
VAS PhGA4. However, there is considerable discrepancy in
the definition of “improvement” and in the duration of
improvement required to define “response.”
One of the most common composite disease activity
scores used was the Polymyalgia Rheumatica Activity Score
(PMR-AS), developed by Leeb and Bird6 and defined as
PMR-AS = CRP (mg/dl) + elevation of upper limbs (0–3) +
0.1 × morning stiffness(min) + VAS patient pain (0–10) +
VAS physician global (0–10)1.
The PMR-AS score showed a good correlation with other
outcome measures, namely with VAS PGA (r = 0.76) and
ESR (r = 0.32)6,33. Given that CRP is a component of
PMR-AS, it is not surprising that the composite score corre-
lated with ESR, which is closely associated with CRP.
Similarly, another component of PMR-AS is the patient pain
VAS; and patient global VAS is usually strongly correlated
with pain VAS. PMR-AS also showed very good internal
consistency in 2 different cohorts (Cronbach-α 0.90 and
0.88)6 and demonstrated reliability3,33,53. 
GC therapy. The characterization of the GC treatment regime
employed is extremely variable. Only a few studies included
the cumulative GC dose21,27,36, the minimum dose
required13,17,21, the duration of therapy21, or the percentage
of discontinuation of steroids after a specified duration of
followup13,20,21,36.
Adverse events. The incidence and characterization of
adverse events related to interventions were described in the
majority of the clinical trials15-24,25, and in the longterm
followup study of patients treated with methotrexate36. None
of the studies performed a systematic and structured evalu-
ation of safety.
Some observational studies were designed to assess
specific adverse events related to GC, such as vertebral
fractures39,42, bone mineral content16,42, cardiovascular and
cerebrovascular events32,42. One study described mortality
and its causes29. The methods used to elicit adverse effects
in observational studies was variable, but death registries and
patient files were the most common sources of information. 
DISCUSSION 
This systematic literature review highlights a remarkable
2507Duarte, et al: Outcome measures in PMR
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variability in the assessment of PMR in research settings.
Patient reported outcomes (PRO) are the most commonly
studied outcomes and were assessed in almost all studies
included in this review. Fatigue, however, was evaluated in
2 studies only. Function and QoL were evaluated in less than
10% of the studies, in spite of their importance to patients54. 
The instruments used to measure PRO in the selected
articles were very heterogeneous. Also, there was, in general,
a poor definition of what is actually being measured (e.g.,
concerning morning stiffness: Is the question referring to the
girdles, the hands, or elsewhere? At what time of the day?
What is the time period being assessed? Are we measuring
duration, severity, or both?). 
There are no studies addressing the relative importance of
each outcome from the patient’s perspective. During
OMERACT 11 (North Carolina, USA, May 2012), the
PMR-SIG Group presented data from a preliminary
“scoping” consultation exercise involving 104 patients with
2508 The Journal of Rheumatology 2015; 42:12; doi:10.3899/jrheum.150515
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Table 3. Summary definitions of good response, remission, relapse, recurrence, and disease activity used in different studies. 
Year Study Good Response Remission Relapse (on GC therapy) or Activity
Recurrence (after GC therapy) Score
1995 Di Munno15 At the end of 2 wks of GC: > 50% of pain, NA NA NA
morning stiffness, ESR and CRP improvement; 
at the end of 12 wks of GC: > 80% of 
improvement in pain and morning stiffness; 
ESR and CRP normal
2000 Cantini28 NA NA Joint signs or symptoms; ESR > NA
30 mm/h; restart or increase GC
2000 Salvarani19 > 70% improvement in pain-VAS, PGA and NA NA NA
PhGA, and morning stiffness
2003 Salvarani24 NA NA Typical symptoms; morning stiffness NA
> 1 h; ESR > 30 mm/h; CRP > 0.5 mg/dl
2004 Caporali20 NA NA Joint signs or symptoms; (aching and NA
stiffness of shoulder, hip girdle or both); 
ESR > 30 mm/h; CRP > 0.5 mg/dl
2005 Salvarani30 NA NA Increase of symptoms; ESR > 30 mm/h NA
or CRP > 0.5 mg/dl; good response after 
increase or restart GC
2007 Catanoso25 EULAR Response Criteria NA NA PMR-AS
2007 Hucthings34 No pain or improvement of > 50% in VAS New symptoms and worsening
girdles-pain; morning stiffness < 30 min; laboratory tests requiring increase of GC
ESR < 30 mm/h and CRP < 1 mg/dl NA NA
2007 Leeb33 NA NA NA PMR-AS
2007 Salvarani21 NA No symptoms or signs; Increase of symptoms (aching and NA
normal ESR stiffness of shoulder, hip girdle or both); 
ESR > 30 mm/h or CRP > 0.5 mg/dl; 
good response after increase or restart GC
2008 Binard35 NA NA NA PMR-AS
2008 Cimmino36 NA NA Joint signs or symptoms; (aching and NA
stiffness of shoulder, hip girdle or both); 
ESR > 30 mm/h; CRP > 0.5 mg/dl
2008 Pulsateli37 NA NA Recurrence of symptoms ESR > NA
30 mm/h; CRP > 0.5 mg/dl; good response 
after restart or increase GC
2009 Machioni38 NA NA Reappearance of clinical manifestations; PMR-AS
ESR > 30 mm/h; CRP > 0.5 mg/dl
2010 Kreiner22 NA NA NA PMR-AS
2011 Cimmino26 NA ≥ 70% improvement in NA NA
clinical symptoms of PMR; 
ESR and CRP normal 1 
month after start therapy
2012 Cleuziou43 NA NA NA PMR-AS
2013 McCarthy45 NA NA NA PMR-AS
2014 McCarthy46 NA NA NA PMR-AS
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; GC: glucocorticoids; PGA: patient global assessment; PhGA: physician global assessment; NA:
not applicable/available; PMR-AS: Polymyalgia Rheumatica Activity Score; VAS: Visual Analog Scale; Relapse (increase of symptoms/signs after remission
or good response, in patients still receiving GC or recurrence (reappearance of symptoms and laboratory changes after remission or good response, following
discontinuation of GC). 
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PMR from 3 centers in the UK and 1 in Belgium. In their
study, patients were invited to express their concerns
regarding disease and treatment. Symptoms and “impair-
ment” were clearly important to patients, with pain, stiffness,
fatigue, and sleep disturbance being mentioned very often.
Physical activity and treatment aspects like GC-related
adverse effects were also considered important54. It is
important that patients’ concerns and wishes are incorporated
into any core outcome set. 
Outcomes assessed by physicians rather than patients were
less heterogeneous. Physician-reported outcomes were used
less frequently in comparison to PRO, with PhGA (0–10 cm
VAS) being the most commonly used. Given the discrep-
ancies between patient and physician evaluations that have
been found in several diseases55,56,57, it is generally
considered that both PRO and physician reported outcomes
should be included to capture the burden of disease. 
All selected articles reported either ESR or CRP, except
in studies designed to evaluate specific adverse
events29,32,41,42. Other laboratory variables, such as IL-6 and
fibrinogen, or US have been considered so far as “experi-
mental” outcomes. 
Disease activity scores or definitions of remission, incor-
porating both physician and patient-reported outcomes are
well-established in other rheumatic diseases and may prove
useful also in PMR. The concepts of remission/relapse/recur-
rence are not consistently defined for PMR. A composite
score of disease activity, the PMR-AS, was developed by
Leeb and colleagues in 200733 and has been used in about
40% of selected articles published after 2007. 
We recognize some strengths and limitations to our study.
We used the most important databases of medical research
articles, considered other languages beside English, and
scrutinized a long period of time. The lack of evaluation of
the quality of papers may be seen as a limitation, but we
believe this was the most adequate strategy to serve the
primary goal of identifying all possible outcomes under
current use. As a limitation, we did not search conference
abstracts or contact the authors in order to enlarge our scope.
By including only longitudinal observational studies and
clinical trials with a PMR population, we may have lost some
outcomes used in cross-sectional studies or in larger studies
of rheumatic diseases. We did not perform any psychometric
analysis of each instrument, as this was outside the intended
scope of this work. 
In conclusion, our study revealed that a great hetero-
geneity exists in the assessment of PMR. Most instruments
have been insufficiently validated according to the
OMERACT Filter, and the patients’ perspective may not
always have been fully covered. These data suggest that
further work is needed to define and validate relevant
outcome measures for assessment of PMR in order to
promote clinical research in this field and enhance compara-
bility of studies. Core areas and domains need to be defined
according to OMERACT procedures. Evaluation instruments
capable of satisfying the properties required by the
OMERACT Filter 2.0 need to be developed, including
validity, reliability, feasibility, and responsiveness. 
REFERENCES
   1.    Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC,
Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid
arthritis and other inflammatory autoimmune rheumatic diseases.
Arthritis Rheum 2011;63:633-9.
   2.    Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N,
et al. EULAR evidence-based recommendations on the management
of systemic glucocorticoid therapy in rheumatic diseases. Ann
Rheum Dis 2007;66:1560-7.
   3.    Binard A, De Bandt M, Berthelot JM, Saraux A. Usefulness of the
disease activity scores for polymyalgia rheumatica for predicting
glucocorticoid dose changes: a study of 243 scenarios. Arthritis
Rheum 2007;57:481-6.
   4.    Leeb BF, Bird HA, Nesher G, Andel I, Hueber W, Logar D, et al.
EULAR response criteria for polymyalgia rheumatica: results of an
initiative of the European Collaborating Polymyalgia Rheumatica
Group (subcommittee of ESCISIT). Ann Rheum Dis 2003;
62:1189-94.
   5.    Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C,
Crowson CS, et al. Definition of remission and relapse in
polymyalgia rheumatica: data from a literature search compared
with a Delphi-based expert consensus. Ann Rheum Dis
2011;70:447-53.
   6.    Leeb BF, Bird HA. A disease activity score for polymyalgia
rheumatica. Ann Rheum Dis 2004;63:1279-83.
   7.    Kirwan JR, Boers M, Tugwell P. Updating the OMERACT filter at
OMERACT 11. J Rheumatol 2014;41:975-7.
   8.    Kirwan JR, Boers M, Hewlett S, Beaton D, Bingham CO 3rd, Choy
E, et al. Updating the OMERACT filter: core areas as a basis for
defining core outcome sets. J Rheumatol 2014;41:994-9.
   9.    Boers M, Kirwan JR, Tugwell P, Beaton D, Bingham CO 3rd,
Conaghan PG, et al. The OMERACT handbook. [Internet. Accessed
March 3, 2015.] Available from:
www.omeract.org/pdf/OMERACT_Handbook.pdf
 10.    Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d’Agostino
MA, et al. Developing core outcome measurement sets for clinical
trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67:745-53.
 11.    Boers M, Kirwan JR, Gossec L, Conaghan PG, D’Agostino MA,
Bingham CO, et al. How to choose core outcome measurement sets
for clinical trials: OMERACT 11 approves filter 2.0. J Rheumatol
2014;41:1025-30.
 12.    Lund B, Egsmose C, Jorgensen S, Krogsgaard MR. Establishment
of the relative antiinflammatory potency of deflazacort and
prednisone in polymyalgia rheumatica. Calcif Tissue Int
1987;41:316-20.
 13.    Littman BH, Bjarnason D, Bryant G, Engelbrecht J, Cohen M,
Mertz L, et al. Steroid sparing activity of tenidap in patients with
polymyalgia rheumatica: a multicenter double blind randomized
placebo controlled study. J Rheumatol 1995;22:1097-103.
 14.    Krogsgaard MR, Lund B, Johnsson B. A longterm prospective study
of the equipotency between deflazacort and prednisolone in the
treatment of patients with polymyalgia rheumatica. J Rheumatol
1995;22:1660-2.
 15.    Di Munno O, Imbimbo B, Mazzantini M, Milani S, Occhipinti G,
Pasero G. Deflazacort versus methylprednisolone in polymyalgia
rheumatica: clinical equivalence and relative antiinflammatory
potency of different treatment regimens. J Rheumatol
1995;22:1492-8.
 16.    Krogsgaard MR, Thamsborg G, Lund B. Changes in bone mass
2509Duarte, et al: Outcome measures in PMR
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2015. All rights reserved.
 Journal of Rheumatology
The on December 15, 2015 - Published by www.jrheum.orgDownloaded from 
during low dose corticosteroid treatment in patients with
polymyalgia rheumatica: a double blind, prospective comparison
between prednisolone and deflazacort. Ann Rheum Dis
1996;55:143-6.
 17.    Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E.
Methotrexate in polymyalgia rheumatica: preliminary results of an
open, randomized study. J Rheumatol 1996;23:624-8.
 18.    Dasgupta B, Dolan AL, Panayi GS, Fernandes L. An initially
double-blind controlled 96 week trial of depot methylprednisolone
against oral prednisolone in the treatment of polymyalgia
rheumatica. Br J Rheumatol 1998;37:189-95.
 19.    Salvarani C, Cantini F, Olivieri I, Barozzi L, Macchioni L, Boiardi
L, et al. Corticosteroid injections in polymyalgia rheumatica: a
double-blind, prospective, randomized, placebo controlled study. 
J Rheumatol 2000;27:1470-6.
 20.    Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C,
Salvarani C, et al. Prednisone plus methotrexate for polymyalgia
rheumatica: a randomized, double-blind, placebo-controlled trial.
Ann Intern Med 2004;141:493-500.
 21.    Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A,
Manganelli P, et al. Infliximab plus prednisone or placebo plus
prednisone for the initial treatment of polymyalgia rheumatica: a
randomized trial. Ann Intern Med 2007;146:631-9.
 22.    Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica:
a randomized controlled trial. Arthritis Res Ther 2010;12:R176.
 23.    Bjorkman MP, Pilvi TK, Kekkonen RA, Korpela R, Tilvis RS.
Similar effects of leucine rich and regular dairy products on muscle
mass and functions of older polymyalgia rheumatica patients: a
randomized crossover trial. J Nutr Health Aging 2011;15:462-7.
 24.    Salvarani C, Cantini F, Niccoli L, Catanoso MG, Macchioni P,
Pulsatelli L, et al. Treatment of refractory polymyalgia rheumatica
with infliximab: a pilot study. J Rheumatol 2003;30:760-3.
 25.    Catanoso MG, Macchioni P, Boiardi L, Pipitone N, Salvarani C.
Treatment of refractory polymyalgia rheumatica with etanercept: an
open pilot study. Arthritis Rheum 2007;57:1514-9.
 26.    Cimmino MA, Parodi M, Montecucco C, Caporali R. The correct
prednisone starting dose in polymyalgia rheumatica is related to
body weight but not to disease severity. BMC Musculoskelet Disord
2011;12:94.
 27.    Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ.
Corticosteroid requirements in polymyalgia rheumatica. Arch Intern
Med 1999;159:577-84.
 28.    Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L,
et al. Erythrocyte sedimentation rate and C-reactive protein in the
evaluation of disease activity and severity in polymyalgia
rheumatica: a prospective follow-up study. Semin Arthritis Rheum
2000;30:17-24.
 29.    Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. Causes of death
in polymyalgia rheumatica. A prospective longitudinal study of 315
cases and matched population controls. Scand J Rheumatol
2003;32:38-41.
 30.    Salvarani C, Cantini F, Niccoli L, Macchioni P, Consonni D,
Bajocchi G, et al. Acute-phase reactants and the risk of
relapse/recurrence in polymyalgia rheumatica: a prospective
followup study. Arthritis Rheum 2005;53:33-8.
 31.    Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, et
al. Relationship between interleukin 6 promoter polymorphism at
position -174, IL-6 serum levels, and the risk of relapse/recurrence
in polymyalgia rheumatica. J Rheumatol 2006;33:703-8.
 32.    Kremers HM, Reinalda MS, Crowson CS, Davis JM 3rd, Hunder
GG, Gabriel SE. Glucocorticoids and cardiovascular and
cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum
2007;57:279-86.
 33.    Leeb BF, Rintelen B, Sautner J, Fassl C, Bird HA. The polymyalgia
rheumatica activity score in daily use: proposal for a definition of
remission. Arthritis Rheum 2007;57:810-5.
 34.    Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K,
Silverman B, et al. Clinical outcomes, quality of life, and diagnostic
uncertainty in the first year of polymyalgia rheumatica. Arthritis
Rheum 2007;57:803-9.
 35.    Binard A, de Bandt M, Berthelot JM, Saraux A. Performance of the
polymyalgia rheumatica activity score for diagnosing disease flares.
Arthritis Rheum 2008;59:263-9.
 36.    Cimmino MA, Salvarani C, Macchioni P, Gerli R, Bartoloni Bocci
E, Montecucco C, et al. Long-term follow-up of polymyalgia
rheumatica patients treated with methotrexate and steroids. Clin Exp
Rheumatol 2008;26:395-400.
 37.    Pulsatelli L, Boiardi L, Pignotti E, Dolzani P, Silvestri T, Macchioni
P, et al. Serum interleukin-6 receptor in polymyalgia rheumatica: a
potential marker of relapse/recurrence risk. Arthritis Rheum
2008;59:1147-54.
 38.    Macchioni P, Catanoso MG, Pipitone N, Boiardi L, Salvarani C.
Longitudinal examination with shoulder ultrasound of patients with
polymyalgia rheumatica. Rheumatology (Oxford) 2009;48:1566-9.
 39.    Calvo L, Pistone G, Arnone S, Colomba D, Amico S, Giacalone A,
et al. Polymyalgia rheumatica and vertebral fractures: a 1-year pilot
controlled study. Rheumatol Int 2010;30:1245-7.
 40.    Jiménez-Palop M, Naredo E, Humbrado L, Medina J, Uson J,
Francisco F, et al. Ultrasonographic monitoring of response to
therapy in polymyalgia rheumatica. Ann Rheum Dis 2010;
69:879-82.
 41.    Kang JH, Sheu JJ, Lin HC. Polymyalgia rheumatica and the risk of
stroke: a three-year follow-up study. Cerebrovasc Dis 2011;
32:497-503.
 42.    Mazzantini M, Torre C, Miccoli M, Baggiani A, Talarico R,
Bombardieri S, et al. Adverse events during longterm low-dose
glucocorticoid treatment of polymyalgia rheumatica: a retrospective
study. J Rheumatol 2012;39:552-7.
 43.    Cleuziou C, Binard A, De Bandt M, Berthelot JM, Saraux A.
Contribution of the polymyalgia rheumatica activity score to 
glucocorticoid dosage adjustment in everyday practice. J Rheumatol
2012;39:310-3.
 44.    Matteson EL, Maradit-Kremers H, Cimmino MA, Schmidt WA,
Schirmer M, Salvarani C, et al. Patient-reported outcomes in
polymyalgia rheumatica. J Rheumatol 2012;39:795-803.
 45.    McCarthy EM, MacMullan PA, Al-Mudhaffer S, Madigan A,
Donnelly S, McCarthy CJ, et al. Plasma fibrinogen is an accurate
marker of disease activity in patients with polymyalgia rheumatica.
Rheumatology (Oxford) 2013;52:465-71.
 46.    McCarthy EM, MacMullan PA, Al-Mudhaffer S, Madigan A,
Donnelly S, McCarthy CJ, et al. Plasma fibrinogen along with
patient-reported outcome measures enhances management of
polymyalgia rheumatica: a prospective study. J Rheumatol
2014;41:931-7.
 47.    Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia
rheumatica: a 10-year epidemiologic and clinical study. Ann Intern
Med 1982;97:672-80.
 48.    Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An
evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis
1979;38:434-9.
 49.    Healey LA. Long-term follow-up of polymyalgia rheumatica:
evidence for synovitis. Semin Arthritis Rheum 1984;13:322-8.
 50.    Jones JG, Hazleman BL. Prognosis and management of polymyalgia
rheumatica. Ann Rheum Dis 1981;40:1-5.
 51.    Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis.
Arthritis Rheum 2000;43:2751-61.
 52.    Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of
the SF-36 version 2 in the United Kingdom. J Epidemiol
Community Health 1999;53:46-50.
 53.    Binard A, Lefebvre B, De Bandt M, Berthelot JM, Saraux A.
2510 The Journal of Rheumatology 2015; 42:12; doi:10.3899/jrheum.150515
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2015. All rights reserved.
 Journal of Rheumatology
The on December 15, 2015 - Published by www.jrheum.orgDownloaded from 
Validity of the polymyalgia rheumatica activity score in primary
care practice. Ann Rheum Dis 2009;68:541-5.
 54.    Mackie SL, Arat S, da Silva J, Duarte C, Halliday S, Hughes R, et
al. Polymyalgia Rheumatica (PMR) Special Interest Group at
OMERACT 11: outcomes of importance for patients with PMR. 
J Rheumatol 2014;41:819-23.
 55.    Kwoh CK, O’Connor GT, Regan-Smith MG, Olmstead EM, Brown
LA, Burnett JB, et al. Concordance between clinician and patient
assessment of physical and mental health status. J Rheumatol
1992;19:1031-7.
 56.    Neville C, Clarke AE, Joseph L, Belisle P, Ferland D, Fortin PR.
Learning from discordance in patient and physician global 
assessments of systemic lupus erythematosus disease activity. 
J Rheumatol 2000;27:675-9.
 57.    Hidding A, van Santen M, De Klerk E, Gielen X, Boers M, Geenen
R, et al. Comparison between self-report measures and clinical
observations of functional disability in ankylosing spondylitis,
rheumatoid arthritis and fibromyalgia. J Rheumatol 1994;21:818-23.
2511Duarte, et al: Outcome measures in PMR
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2015. All rights reserved.
 Journal of Rheumatology
The on December 15, 2015 - Published by www.jrheum.orgDownloaded from 
